RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación
Artículo científico (JournalArticle)
Disruption of MCL1/BOK transmembrane interaction as a novel strategy to induce cell death in tumours
[EN] MCL1, an anti-apoptotic BCL-2 family member, is frequently overexpressed in multiple tumour types and correlates with poor prognosis; however, targeting its cytosolic domain to release pro-apoptotic effectors has been limited by cardiotoxicity in clinical trials. In this study, we describe a chemically mediated disruption of the MCL1/BOK transmembrane interaction that induces tumour cell death without affecting viability in 3D cardiomyocyte cultures. Molecular dynamics simulations and LUV-based assays converged to show that the MBoIN179 disrupts transmembrane dimerization, thereby restoring BOK pore formation inhibited by MCL1. In cells, interference with the MCL1/BOK transmembrane interaction promoted relocalization of BOK from the endoplasmic reticulum to mitochondria, where it engaged a BOK-dependent cell death program in both 2D and 3D breast cancer models, leading to reduced tumour growth and metastasis in vivo. Analysis of patient tumour microarrays further showed that BOK is overexpressed in aggressive breast cancer subtypes and correlates with poor prognosis. Together, these findings identify the MCL1/BOK transmembrane interaction as a tumour-selective vulnerability that can be engaged to promote antitumour responses with cardiac safety, highlighting transmembrane interactions as viable molecular targets., These results are part of the project PID2023-148234NB-I00, funded by MCIU/AEI/
10.13039/501100011033 and ERDF/EU, project PT23/00177, funded by Instituto de
Salud Carlos III (ISCIII) and co-funded by the European Union, and the project
CIPROM/2022/62, funded by the Department of Education, Culture, Universities and
Employment of the Generalitat Valenciana (PROMETEO). A part of the work was also
supported by grants from the Spanish Ministry of Economy and Innovation (PID2019-
104644RB-I00 -GMB-) and the Instituto de Salud Carlos III (CIBERONC, CB16/12/00295
-GMB). MB is funded by a predoctoral fellowship (GRISOLIAP/2021/132) from
Generalitat Valenciana and by an EMBO Scientific Exchange Grant (11082) for a
research stay in the laboratory of Ana García-Sáez. DL is funded by a predoctoral
fellowship (PRDVA21475LEIV) from the Spanish Cancer Association (AECC). RS and
AGS are partially funded by the Deutsche Forschungsgemeinschaft (CRC1403, project
414786233; TRR353, project 471011418). This work is also supported by grants of the
Deutsche Forschungsgemeinschaft (DFG) to FL (SFB-1638/1 511488495 - Z01).
Proyecto:
Agencia Estatal de Investigación / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 PID2019-104644RB-I00
,
Agencia Estatal de Investigación / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PID2023-148234NB-I00
,
Ministerio de Economía y Competitividad CB16/12/00295
,
Instituto de Salud Carlos III PT23/00177
,
Generalitat Valenciana CIPROM/2022/62
,
Deutsche Forschungsgemeinschaft SFB-1403 414786233
,
Deutsche Forschungsgemeinschaft SFB-1638/1
,
Generalitat Valenciana GRISOLIAP/2021/132